UBS Raises Biogen (BIIB) Price Target to $270

UBS has maintained its Buy rating on Biogen Inc. and raised its price target to $270, a 15.61% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:14 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

UBS raised its price target on Biogen Inc. ($BIIB) to $270 from $240 on October 9, 2026, and rates the stock "Buy".

Since the rating, $BIIB is up 3.1% after 1 week and up 3.1% to date (from the $225.71 close on Oct 9, 2026).

BIIB Biogen Inc.

$232.65 +30.83% year to date

Daily close · Oct 16, 2026

Key Points

On October 9, 2026, UBS reiterated its Buy rating on Biogen Inc. (NasdaqGS: BIIB) with a new price target of $270, up from $240.
UBS's $270 price target implies 15.61% upside from Biogen Inc.'s ($BIIB) current $233.54 share price.
As of October 16, 2026, Biogen's stock was recently trading at $233.54, which is about 13.5% below UBS's new target.
Biogen's next earnings report is scheduled for October 28, 2026, which may provide further insights into its financial performance.

Get $BIIB trade alerts by text

We text you when insiders, Congress or big funds trade $BIIB. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Biogen Inc. alert may contain errors. Disclosures

UBS has maintained its Buy rating on Biogen Inc. (NasdaqGS: BIIB) and raised its price target to $270 on October 9, 2026, up from a prior target of $240. The stock was recently trading at $233.54 on October 16, 2026, which places it about 13.5% below the new target.

Other Institutional Activity in Biogen

FMR, LLC increased its stake by 5,409,844 shares, bringing its total to 18,217,239 shares worth approximately $4.24 billion. Blackrock Inc. added 11,182 shares, ending with 15,985,736 shares valued at about $3.72 billion. Primecap Management Company raised its holdings by 396,980 shares, totaling 15,154,606 shares worth around $3.53 billion. Vanguard Capital Management LLC grew its position by 113,498 shares, reaching 9,651,117 shares valued at about $2.25 billion. State Street Corporation increased its stake by 176,333 shares, totaling 7,344,327 shares worth approximately $1.71 billion.

Biogen Inc. Stock Down 0.8%

Biogen's stock is currently trading at $233.54, which is below the new price target of $270 set by UBS. This suggests potential upside for investors, especially as the stock is positioned below the analyst's expectations.

12-month forecast

$BIIB price target

Biogen Inc. daily closes and this analyst's $270 target. Not advice.

Recent Earnings

Biogen reported trailing twelve-month revenue of approximately $10.03 billion and an EPS of $5.62. The company has a net margin of 8.3% and a return on equity of 4.6%. Its next earnings date is set for October 28, 2026, which could provide more clarity on its financial trajectory.

Earnings drift grade

Outlook vs expectations on the last report — not price action.

B- 71/100

Reported Apr 29, 2026

Forward outlook
5 target raises vs 1 cuts.
EPS & revenue
EPS beat estimates by 26.3%. Revenue beat estimates by 7.7%.
Profit surprise
EBITDA missed by 7 percent. Operating income missed by 14 percent.
Pre-earnings setup
Expectations were about average.
Analyst signal
5 target raises, 1 target cut.
Earnings quality
Gross margin down 2.9 points. Operating margin down 14.1 points. Positive free cash flow.

Earnings Call Summary

Biogen had a very strong first quarter with growth products generating 851 million dollars, up 12 percent year-over-year. LEQEMBI sales surged 74 percent to 168 million dollars, benefiting from expansion in the U.S., Japan, and China. The company highlighted real-world evidence showing nearly 80 percent of LEQEMBI patients remain on therapy at 18 months, supporting the durability of treatment. High-dose SPINRAZA launched successfully with 20 percent of U.S. patients already switching, and the company is preparing for multiple pipeline readouts starting this year, including data on tau-targeting drug BIIB080 and lupus candidate Litifilimab.

Guidance Biogen reaffirmed its full-year guidance, confident in underlying business strength. The company expects to close the Apellis acquisition in the second quarter and will provide combined guidance after close. Management noted about 600 million dollars of contract manufacturing revenue expected this year, roughly two-thirds in the first half. They anticipate the acquisition will be accretive to earnings per share in 2027.

Slightly positive report. The quarter was acceptable, but the forward setup is not strong.

Insider Buying and Selling at Biogen Inc.

Recent insider transactions include Nicole Murphy, an officer, who bought 3 shares at an average price of $195.04 on February 12, 2026, totaling $585. Additionally, Priya Singhal, another officer, sold 2,660 shares at an average price of $199.83 on February 9, 2026, for a total value of about $531,548. Lloyd B. Minor, a director, sold 1,186 shares on August 4, 2026, valued at approximately $239,750.

Analysts Set New Price Targets

On October 9, 2026, UBS reiterated its Buy rating on Biogen with a new target price of $270, up from $240. Earlier, RBC Capital maintained its Outperform rating with a target of $256 on October 8, 2026, while Piper Sandler reiterated its Overweight rating with a target of $245 on September 3, 2026. The consensus among analysts suggests a positive outlook for Biogen, with a range of targets indicating potential growth.

About Biogen

Biogen Inc. is a biotechnology company that discovers, develops, manufactures, and delivers therapies for neurological diseases and other serious conditions. Headquartered in Cambridge, Massachusetts, Biogen plays a significant role in the healthcare sector, especially in drug manufacturing. The recent analyst activity reflects confidence in its future performance.

Bottom Line

Investors should monitor Biogen's upcoming earnings report on October 28, 2026, as it may provide insights into the company's performance and future outlook. UBS's recent rating and target adjustment suggest that analysts remain optimistic about Biogen's potential despite the current trading price.